A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Durvalumab (Primary) ; Neoantigen DNA vaccine Washington University School of Medicine/MedImmune (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 24 Oct 2017 Planned End Date changed from 30 Sep 2020 to 30 Nov 2020.
- 24 Oct 2017 Planned primary completion date changed from 31 Mar 2020 to 31 May 2020.
- 24 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 31 Dec 2017.